Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating Costs and Expenses:    
General and administrative $ 4,580 $ 5,727
Research and development 11,083 11,844
Total Operating Costs and Expenses 15,663 17,571
Loss from Operations (15,663) (17,571)
Other Income :    
Change in fair value of warrant liability 0 4,083
Interest income 283 67
Total Other Income 283 4,150
Net Loss (15,380) (13,421)
Net Loss Attributable to Non-controlling Interest (77) (54)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (15,303) (13,367)
Preferred Stock Dividends, Income Statement Impact (248) (243)
Net Loss Attributable to Common Stockholders $ (16,076) $ (25,291)
Net Loss Per Share - Basic and Dilutive $ (0.98) $ (4.06)
Weighted average number of shares outstanding during the period - Basic and Dilutive 16,438,201 6,232,442
Series A Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact $ (248) $ (243)
Series B Preferred Stock [Member]    
Other Income :    
Net Loss Attributable to Non-controlling Interest 0 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0
Preferred Stock Dividends, Income Statement Impact $ (525) $ (11,681)